Abstract
D&MD's Organic and Medicinal Chemistry in Drug Discovery Report analyzes the methods and technologies currently used to craft compound collections as well as the products and services available in support of pharma's chemistry programs. This Report critically evaluates both existing and emerging technologies for organic synthesis and compound design. In addition, the technology and market trends in organic and medicinal chemistry for drug discovery are discussed in depth, and current sales and market projections for outsourcing products and services are also provided. This Report offers the views of key industry participants on the state of and future prospects for organic and medicinal chemistry in drug discovery. This data was obtained through a proprietary market survey conducted by D&MD publications In addition to the survey, in-depth interviews were conducted with chemists and managers in pharma, biopharma, and vendor organizations. The inclusion of the history and evolution of organic and medicinal chemistry in pharma provides perspective on current approaches and future directions
Table of Contents
Chapter 1: Executive Summary
- Evolution of Organic and Medicinal Chemistry in the Pharmaceutical Industry
- Current Approaches to Organic and Medicinal Chemistry
- Products and Services
- Organic and Medicinal Chemistry Market
- Scope and Nature of the Report
Chapter 2: Evolution of Organic Chemistry in the Pharmaceutical Industry
- Evolution of Organic and Medicinal Chemistry in Pharma
- Industrialization of Drug Discovery
- Advent of Combinatorial Chemistry
- Chemical Diversity
- Lead-Likeness and Drug-Likeness
- References
Chapter 3: Current Approaches to Organic and Medicinal Chemistry
- "Classical" Chemical Library Generation
- Split-and-Mix Chemistry
- Parallel Synthesis
- Newer Synthetic Approaches
- tructure-Based and Fragment-Based Design
- Natural Products Renaissance
- Diversity-Oriented Synthesis
- Dynamic Chemical Libraries and Click Chemistry
- Dynamic Chemical Libraries
- Click Chemistry
- Chemogenomics
- Role of the NIH
- Current Practices in Organic and Medicinal Chemistry in Pharma
- References
Chapter 4: Products and Services
- Technological Approaches of Vendors and Biopharmaceutical Companies
- Structure-Based Design
- Diversity-Oriented Synthesis
- Chemogenomics
- Multi-Component Reaction Chemistry
- Other Approaches
- Product Offerings
- Service Offerings from Selected Vendors
Chapter 5: The Organic and Medicinal Chemistry Market
- The Competitive Environment
- Business Models
- Collaborations, Strategic Alliances, and Other Deals
- Market Analysis
- Market Survey Results
- General Observations
- References
Chapter 6: Company Profiles
- Accelrys, Inc.
- Albany Molecular Research, Inc.
- AnalytiCon Discovery GmbH
- ArQule, Inc.
- Asinex Ltd.
- Astex Therapeutics
- Biotage AB
- Cellular Genomics Inc.
- ChemBridge Corporation
- Chemical Diversity Labs, Inc.
- Daylight Chemical Information Systems, Inc.
- Discovery Partners International
- De Novo Pharmaceuticals Ltd.
- Eidogen-Sertanty, Inc.
- Enamine
- Evotec OAI
- Exelixis
- Graffinity Pharmaceuticals AG
- Infinity Pharmaceuticals
- Locus Pharmaceuticals
- Morphochem AG
- Nanosyn
- Nuevolution A/S
- Pharmacopeia Drug Discovery, Inc.
- Plexxikon Inc.
- Schrodinger, Inc.
- Structural GenomiX
- Surface Logix, Inc.
- Syrrx, Inc.
- Tripos, Inc.
- Vernalis plc
Chapter 7: Interviews With Industry Experts
- Michael Foley, Ph.D., Vice President, Chemistry, Infinity Pharmaceuticals
- Malcolm MacCoss, Ph.D., Vice President of Chemistry and Drug Discovery Sciences, Merck
- Horst Hemmerle, Ph.D., Head Lead Generation, Discovery Chemistry, Eli Lilly & Co.
- James Inglese, Ph.D., Director, Biomolecular Screening and Profiling Division, NIH Chemical Genomics Center
- Alexander S. Kiselyov, Ph.D., Vice President of Chemistry, Chemical Diversity Labs, Inc.
- Michael Morrissey, Ph.D., Senior VP of Discovery, Exelixis
- Steven Muskal, Ph.D., CEO, Eidogen-Sertanty, Inc.
